Just when you thought the world couldnt get any spookier, say hello to the newly born xenobot, a new kind of living thing.
Its hard to say with certainty who the father is.
Or maybe its just hard to admit whats actually happened: Like a bright child making a weirdo companion from Play-Doh, artificial intelligence has mated with the living cells of a frog to create an eerie hybrid of life and machine.
In a statement from the University of Vermont (UVM), the researchers explain it this way: A team of scientists has repurposed living cells, scraped from frog embryos, and assembled them into entirely new life forms.
These millimetre-wide xenobots can live for weeks, travel about with intent, work in groups autonomously, and heal themselves after being cut.
The idea is they could be set sail in their billions to clean the oceans of microplastics.
The really smart ones could be stationed in your organs, where theyd carry out renovating surgery or deliver drugs.
These are novel living machines, says Professor Joshua Bongard, a computer scientist and robotics expert at the University of Vermont who co-led the research.
Theyre neither a traditional robot, nor a known species of animal. Its a new class of artefact: A living, programmable organism.
The new creatures were designed on the Deep Green supercomputer at UVM and then assembled and tested by biologists at Tufts University.
The Deep Green supercomputer cluster at UVMs Vermont Advanced Computing Core used an evolutionary algorithm to create thousands of candidate designs for the new life forms.
Essentially, the computer was told here are your buildings blocks, literally abstract cubes with the physical parameters and limitations of skin and heart cells of an African frog.
The computer was then given an assignment: Arrange the cells so they could move forward. Or side to side. Or herd tiny sheep (no kidding).
And this is where the Play-Doh analogy comes in: The computer would, over and over, reassemble a few hundred simulated cells into myriad forms and body shapes. Is this one OK? What about this one?
Following the same pattern as human beings leaving behind its long-dead ancestors, Homo Erectus and the other hominins that followed, some of the creatures were selected to survive, but the less-successful species went extinct and were tossed to oblivion.
Eventually, the most promising designs were selected for testing.
And this is where it gets spooky.
Because the next step was to bring those building blocks, those red and green cubes, to life.
Here the research shifted from the UVM supercomputer to the biology labs at Tufts University, where stem cells were harvested from the embryos of African frogs, the species Xenopus laevis. (from which the name xenobot is derived).
The cells were separated into single cells and left to incubate.
The creepy yet wondrous thing is, not kept apart, the cells clump together and try to make something of themselves.
Next step: A microsurgeon, Dr Douglas Blackiston, used tiny forceps and an even tinier electrode, to cut the cells and join them under a microscope into a close approximation of the designs specified by the computer.
Assembled into body forms never seen in nature, the cells began to work together, the researchers advise.
The skin cells formed a more passive architecture, while the once-random contractions of heart muscle cells were put to work creating ordered forward motion as guided by the computers design, and aided by spontaneous self-organising patterns allowing the robots to move on their own.
These reconfigurable organisms were shown to be able move in a coherent fashion and explore their watery environment for days or weeks, powered by embryonic energy stores.
Turned over, however, they failed, like beetles flipped on their backs.
Later tests showed that groups of xenobots would work together like cowboys, moving around in circles, pushing pellets into a central location.
They did this spontaneously and collectively. Others were built with a hole through the centre to reduce drag.
In simulated versions, the scientists were able to repurpose this hole as a pouch to successfully carry an object.
We can imagine many useful applications of these living robots that other machines cant do, said co-leader Professor Michael Levin who directs the Centre for Regenerative and Developmental Biology at Tufts, like searching out nasty compounds or radioactive contamination, gathering microplastic in the oceans, travelling in arteries to scrape out plaque.
That fear is not unreasonable, Dr Levin said. When we start to mess around with complex systems that we dont understand, were going to get unintended consequences.
How might the creatures eventually work together in bigger systems?
As the researchers admit, who the heck knows?
A lot of complex systems, like an ant colony, begin with a simple unit an ant from which it would be impossible to predict the shape of their colony or how they can build bridges over water with their interlinked bodies.
Dr Levin said its an absolute necessity for society going forward to get a better handle on systems where the outcome is very complex.
A first step towards doing that is to explore: How do living systems decide what an overall behaviour should be and how do we manipulate the pieces to get the behaviours we want?
In other words, he suggested: This study is a direct contribution to getting a handle on what people are afraid of, which is unintended consequences.
If this was a horror movie, it would go like this: The world is under siege from a malevolent virus.
The frightened populace can think of nothing else.
Meanwhile, creepy monsters made from frog skin decide to take over the joint
See more here:
Half frog, half machine: The rise of the xenobot - The New Daily
- RMS Sponsors the 5th Summit on Stem Cell Derived Islets - The Manila Times - October 30th, 2024
- Differentiation fate of a stem-like CD4 T cell controls immunity to cancer - Nature.com - October 30th, 2024
- Self-organization of stem cells into embryos: A window on early ... - October 24th, 2024
- Stemness and ROS: Redox Signaling and Regulation in Stem Cell Biology - Frontiers - October 24th, 2024
- Now its getting bloody in cardiac organoids - Nature.com - October 18th, 2024
- Embryonic stem cells - PMC - National Center for Biotechnology Information - October 15th, 2024
- They Were Made Without Eggs or Sperm. Are They Human? - The Atlantic - October 15th, 2024
- A novel investigation of NANOG and POU5F1 associations in the pluripotent characterization of ES-like and epiblast cells - Nature.com - October 15th, 2024
- Researchers uncover new mechanism of stem cell differentiation linked to cancer progression - News-Medical.Net - October 14th, 2024
- Stem Cells to Reverse Diabetes, the Spread of Marburg Virus and Map of a Fruit Fly Brain - Scientific American - October 14th, 2024
- Stem Cells Market Expectation Surges with Rising Demand and Changing Trends - openPR - October 11th, 2024
- How close are we to perfecting synthetic stem cells? - The Mancunion - October 10th, 2024
- Blood-generating heart-forming organoids recapitulate co-development of the human haematopoietic system and the embryonic heart - Nature.com - October 10th, 2024
- Revolutionary stem cell transplant successfully closes vision-threatening holes in the eye - Study Finds - October 4th, 2024
- Early human development and stem cell-based human embryo models - October 4th, 2024
- No partner, no problem: How people in the future might be able to have children with themselves - RNZ - October 4th, 2024
- Californias Billion-Dollar Stem Cell Initiatives End In Failure OpEd - Eurasia Review - October 4th, 2024
- The Future Of Stem Cell Therapy With Dr Adeel Khan - Style Magazines - October 4th, 2024
- New Study Mapping Stem Cells Reveals Molecular Choreography Behind ... - September 30th, 2024
- Stem Cell Research at Johns Hopkins Institute of Basic Biomedical ... - September 30th, 2024
- Zack Wang , PhD - Hopkins Medicine - September 30th, 2024
- Jennifer Hartt Elisseeff , PhD - Hopkins Medicine - September 30th, 2024
- Dr. Elias Zambidis, MD, PhD - Baltimore, MD - Pediatric Cellular ... - September 30th, 2024
- Alan David Friedman , MD - Hopkins Medicine - September 30th, 2024
- Targeted therapy of cancer stem cells: inhibition of mTOR in pre-clinical and clinical research - Nature.com - September 30th, 2024
- Human Embryonic Stem Cells Market Insights and Growth Trends: Leading Players and Future Projections to 2031 - WhaTech - September 26th, 2024
- Zac Efron says stem cell therapy helped him heal from The Iron Claw injuries - Daily Mail - September 25th, 2024
- The Role of Stem Cell Therapy in the Future of Personalized Medicine - HIT Consultant - September 25th, 2024
- Stem Cell Therapy Market to Exceed $831.9 Million by 2032 with 17.2% CAGR Growth - openPR - September 14th, 2024
- Brain Builders: How Stem Cell Research Is Rewriting the Genetic Code of Mental Health - SciTechDaily - September 14th, 2024
- Pausing biological clock could give boost to lab-produced blood stem cells - Phys.org - September 10th, 2024
- Alive and Kicking: Watch this space on controversy-free stem-cell ... - September 8th, 2024
- After 25 years of hype, embryonic stem cells still don't cure for ... - September 8th, 2024
- Human embryonic stem cells: origin, properties and applications - September 8th, 2024
- Livestock embryonic stem cells for reproductive biotechniques and ... - September 8th, 2024
- Marinexcell: Our Vision Is To Create a Sustainable and Reliable Source of Seafood Products - vegconomist - the vegan business magazine - September 6th, 2024
- How cells enter the germline at the right time and place during embryonic development - MRC Laboratory of Molecular Biology - September 6th, 2024
- Diabetes took over her life, until a stem cell therapy freed her - redlakenationnews.com - August 31st, 2024
- Diabetes took over her life, until a stem cell therapy freed her - The Washington Post - August 27th, 2024
- New way to extend shelf life of blood stem cells will improve gene therapy - University of Cambridge news - August 20th, 2024
- The anti-aging tech guy is now shooting $25,000 worth of stem cells into his knees. Here's why - Quartz - August 16th, 2024
- Substrates mimicking the blastocyst geometry revert pluripotent stem cell to naivety - Nature.com - August 12th, 2024
- Delivery of stem cell therapy for Parkinsons safe in primate trial - Parkinson's News Today - August 2nd, 2024
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - July 31st, 2024
- Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 - July 31st, 2024
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update - July 31st, 2024
- PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024 - July 31st, 2024
- Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 - July 31st, 2024
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 - July 31st, 2024
- Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency... - July 31st, 2024
- Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024 - July 31st, 2024
- Appendix 4C – Q4 FY24 Quarterly Cash Flow Report - July 31st, 2024
- Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation - July 31st, 2024
- Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its... - July 31st, 2024
- Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference - July 31st, 2024
- Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors - July 31st, 2024
- electroCore to Announce Second Quarter June 30, 2024 Financial Results on Wednesday, August 7, 2024 - July 31st, 2024
- GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 - July 31st, 2024
- New Study: These Bizarre Blood-Sucking Fish Have a Jaw-Dropping Evolutionary Origin - SciTechDaily - July 30th, 2024
- Surgeon Turns to Stem Cells to Help Treat Autism and Immune Disorders - The Well News - July 22nd, 2024
- Study identifies epigenetic 'switches' that regulate the developmental trajectories of single cells - Medical Xpress - July 22nd, 2024
- German Man Likely 'Cured' of HIV With Stem Cell Therapy - Times Now - July 22nd, 2024
- CervoMed to Participate in the Emerging Growth Conference - July 18th, 2024
- Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives - July 18th, 2024
- Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification - July 18th, 2024
- Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of... - July 18th, 2024
- Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of... - July 18th, 2024
- Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study - July 18th, 2024
- New Nature publication confirms CARBIOS’ leadership in enzymatic degradation of plastic - July 18th, 2024
- Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - July 18th, 2024
- Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma - July 18th, 2024
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal - July 18th, 2024
- Scorpius Holdings Announces Reverse Stock Split - July 18th, 2024
- Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines - July 18th, 2024
- Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe... - July 18th, 2024
- Q2 2024 Revenue and Business Highlights, Guidance Upgrade - July 18th, 2024
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line... - July 18th, 2024
- Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance - July 18th, 2024
- BioSenic releases new in-depth analysis of its positive phase 2 clinical data for optimal administration scheme for its next late-stage trial of... - July 18th, 2024
- Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and... - July 18th, 2024
Recent Comments